· Published by Health Canada · Official notice
This is duplicated text of a letter from Boehringer Ingelheim (Canada) Ltd. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
June 29, 2006
Dear Health Care Professional,
Subject: Important Safety Information: Intracranial Hemorrhage in Patients Receiving Aptivus® (tipranavir) Capsules
Boehringer Ingelheim (Canada) Ltd., following discussion with Health Canada, is writing to inform you of important new safety information for APTIVUS. APTIVUS co-administered with low dose ritonavir is indicated for combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are treatment experienced and have HIV-1 strains resistant to multiple protease inhibitors.
Boehringer Ingelheim (Canada) Ltd. is currently working with Health Canada to revise the Warnings and Precautions, and Consumer Information sections of the APTIVUS Product Monograph.
A copy of this Dear Health Care Professional Letter will be posted on Boehringer Ingelheim’s (www.boehringer-ingelheim.ca) web site.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of intracranial hemorrhage or other serious or unexpected adverse events in patients receiving APTIVUS should be reported to Boehringer Ingelheim (Canada) Ltd. or Health Canada at the following addresses:
Boehringer Ingelheim (Canada) Ltd.
Manager, Drug Safety
5180 South Service Road
Burlington, Ontario L7L 5H4
Or call toll free at 1-800-263-5103 Ext. 4603
Or Fax at: 905-333-4464
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Bureau of Gastroenterology, Infection and Viral Diseases (BGIVD)
E-mail: BGIVD_Enquiries@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738